Table 2.

Characteristics of side effects

	EVG/c/FTC/TAF	DOR/3TC/TDF	p-value
	n = 128	n = 94
Occurrence of at least one side effect, n (%)	38 (29.7%)	36 (38%)	0.11
Discontinuation of treatment due to poor tolerance	5 (3.9%)	1 (1.1%)	0.40
Clinical side effects
Digestive side effect: nausea or vomiting n (%)	14 (10.1%)	13 (13.8%)
Digestive side effect: diarrhea, n (%)	8 (6.2%)	8 (8.5%)
Rash	2 (1.6%)	1 (1.1%)
Mucous membrane lesions	0	1 (1.1%)
Headache	2 (1.6%)	1 (1.1%)
Fatigue, discomfort	2 (1.6%)	5 (5.3%)
Myalgia	0	1 (1.1%)
Sleep disorders, anxiety	0	1 (1.1%)
Dysgueusia	0	1 (1.1%)
Hypersalivation	0	1 (1.1%)
Increase in AST and ALT	3 (2.3%)	0
Not specified	6 (4.7%)	9 (9.6%)
Impact on daily life, n	n = 125	n = 89
No discomfort, n (%)	103 (82.4%)	67 (75.3%)
Moderate discomfort, n (%)	16 (12.8%)	19 (21.3%)
Significant discomfort, n (%)	5 (4%)	3 (3.4%)
Major discomfort, n (%)	1 (0.8%)	0